OTCMKTS:ARSUF Fagron (ARSUF) Stock Price, News & Analysis $26.53 0.00 (0.00%) As of 05/22/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartShort InterestBuy This Stock About Fagron Stock (OTCMKTS:ARSUF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Fagron alerts:Sign Up Key Stats Today's Range$26.06▼$26.5350-Day Range$26.53▼$27.0052-Week Range$26.00▼$27.00VolumeN/AAverage Volume2,633 shsMarket CapitalizationN/AP/E RatioN/ADividend Yield2.04%Price TargetN/AConsensus RatingN/A Company Overview Fagron (OTCMKTS:ARSUF) is a global pharmaceutical compounding company that supplies raw materials, equipment and services to compounding pharmacies, hospitals and healthcare practitioners. Its portfolio encompasses a range of pharmaceutical ingredients, dosage forms and specialized compounding solutions designed to meet patient-specific needs. The company supports the preparation of customized medications in areas such as dermatology, pain management, hormone replacement therapy and veterinary medicine, providing both sterile and non-sterile compounding products. Headquartered in Rotterdam, the Netherlands, Fagron operates in more than 55 countries across Europe, the Americas, Asia-Pacific and the Middle East & Africa. The organization maintains a network of local laboratories and logistics centers to ensure compliance with regional regulations and to expedite delivery of critical compounding materials. Through its subsidiaries, Fagron offers technical training, regulatory consulting and quality assurance services, helping pharmacies and healthcare facilities to maintain high standards of safety and efficacy. Since its founding in the early 2000s, Fagron has grown through organic expansion and targeted acquisitions, broadening its product range and geographic footprint. While the company is listed on Euronext Brussels, its American Depositary Receipts trade on the over-the-counter market under the symbol ARSUF. Fagron’s management team blends expertise in pharmaceutical science, supply chain operations and international business development to drive innovation in personalized medicine and to support the evolving needs of compounding professionals worldwide.AI Generated. May Contain Errors. Read More Receive ARSUF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fagron and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARSUF Stock News HeadlinesFagron shareholders approve all proposed resolutions at the General MeetingsMay 11, 2026 | globenewswire.comFagron convenes Ordinary and Extraordinary General Meeting on 11 May 2026April 10, 2026 | globenewswire.com$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker.May 23 at 1:00 AM | Paradigm Press (Ad)Fagron reports solid first-quarter revenue of €263 million, reflecting 10% topline growthApril 9, 2026 | globenewswire.comFagron NV (ARSUF) Q3 2025 Sales Call TranscriptOctober 9, 2025 | seekingalpha.comRecord revenue of €209 million in first quarter reflecting 15% topline growthApril 11, 2024 | globenewswire.comFagron delivers topline growth of 21.5% to €173 millionOctober 13, 2022 | finance.yahoo.comFagron commits to set science-based emission reduction targetsSeptember 27, 2022 | finance.yahoo.comSee More Headlines ARSUF Stock Analysis - Frequently Asked Questions How have ARSUF shares performed this year? Fagron's stock was trading at $23.50 at the beginning of 2026. Since then, ARSUF shares have increased by 12.9% and is now trading at $26.5296. How do I buy shares of Fagron? Shares of ARSUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today5/23/2026Next Earnings (Estimated)7/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:ARSUF CIKN/A Webwww.fagron.com Phone32.8.001.28.80FaxN/AEmployees3,282Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free Report This page (OTCMKTS:ARSUF) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fagron NV Please log in to your account or sign up in order to add this asset to your watchlist. Share Fagron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.